Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Deals of the Week: Stada/Grunenthal, Stada/Spirig, Shire/Sangamo

Executive Summary

While 2012 promises to be a lucrative for generic drug companies, they now face their own reverse patent cliff. Some, therefore, are looking to diversify into branded products.


Related Content

Merck KGaA Draws A Line Under “Old” R&D, Now Seeks More Deals
Shire Buys FerroKin BioSciences To Further Hematology Strategy
Genzyme Restart Won’t Hobble Shire’s 2012 Prospects, Shire’s Gregoire Says
With Nycomed, Takeda Satifies Both Strategic And Financial Objectives
BioPontis Aims To Bridge "Valley Of Death"


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts